Monographie - Etoposide

Etoposide

Kemiallinen rakenne

Kauppanimi

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Eposin	Belgia, Etelä-Afrikka, Iso-Britannia, Kolumbia, Malesia, Norja, Ruotsi
Etocris	Argentiina, Chile, Marokko
Etolon	Intia
Etomedac	Luxemburg, Saksa
Etonolver	Venezuela
Etoposide	Hollanti, Kreikka, Ranska
Etosid	Egypti, Intia, Malesia
Eunades	Brasilia
Euvaxon	Argentiina
Exitop	Ruotsi, Saksa, Suomi
Fytosid	Egypti, Intia, Malesia
Lastet	Egypti, Iran, Italia, Puola, Turkki, Unkari, Yhdistyneet arabiemiirikunnat
Onkoposid	Saksa
Riboposid	Saksa
Sedol	Marokko
Toposin	Hollanti
Tosuben	Meksiko
Vepesid	Australia, Belgia, Egypti, Espanja, Etelä-Afrikka, Hollanti, Irlanti, Italia, Itävalta, Kanada, Kolumbia, Kreikka, Kroatia, Luxemburg, Puola, Saksa, Saudi-Arabia, Slovenia, Suomi, Sveitsi, Tanska, Turkki, Unkari, Yhdysvallat
Vepeside	Marokko, Tunisia

Viitteet : Etoposide

	Tyyppi	Julkaisu
3	Lehti	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
57	Lehti	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
81	Lehti	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Lehti	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
85	Lehti	Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 1716-1719.
91	Lehti	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
99	Lehti	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
140	Lehti	Pearson SD, Trissel LA. Leaching of diethylhexyl phthalate from polyvinyl chloride containers by selected drugs and formulation components. Am J Hosp Pharm 1993 ; 50: 1405-1409.
150	Lehti	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
152	Lehti	Chevrier R, Sautou V, Pinon V, Demecop F, Chopineau J. Stability and compatibility of a mixture of the anti-cancer drugs etoposide, cytarabine and daunorubicine for infusion. Pharm Acta Helv 1995 ; 70: 141-148.
161	Lehti	Barthes DM, Rochard EB, Pouliquen IJ, Rabouan SM, Courtois PY. Stability and compatibility of etoposide in 0.9% sodium chloride injection in three containers. Am J Hosp Pharm 1994 ; 51: 2706-2709.
169	Lehti	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Lehti	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
184	Lehti	Stewart JT, Warren FW, King DT, Fox JL. Stability of ondansetron hydrochloride and five antineoplasic medications. Am J Health-Syst Pharm 1996 ; 53: 1297-1300.
244	Lehti	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Lehti	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Lehti	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
307	Lehti	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
331	Lehti	Marquardt ED. Visual compatibility of hydroxyzine hydrochloride with various antineoplasic agents. Am J Hosp Pharm 1988 ; 45: 2127.
334	Lehti	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Lehti	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
417	Lehti	Stewart CF, Hampton EM. Stability of cisplatin and etoposide in intravenous admixtures. Am J Hosp Pharm 1989 ; 46: 1400-1404.
482	Lehti	Beijnen JH, Beijnen-Bandhoe U, Dubbelman AC, Van Gijn R, Underberg WJM. Chemical and physical stability of etoposide and teniposide in commonly used infusion fluids. J Parenter Sci Technol 1991 ; 45: 108-112.
491	Lehti	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	Lehti	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
504	Lehti	Hamon M, Plas-Remoissenet D, Kubab-Alajati S. Etude de la stabilité dans des solutions diluées destinées à la perfusion de deux antimitotiques dérivés de la podophyllotoxine : l’étoposide (VP 16), le téniposide (VM 26). Sci Tech Pharm 1987 ; 3: 33-40.
643	Lehti	Seargeant LE, Kobrinsky NL, Sus CJ, Nazeravich DR. In vitro stability and compatibility of daunorubicin, cytarabine, and etoposide. Cancer Treat Rep 1987 ; 71: 1189-1192.
905	Lehti	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
1026	Lehti	Mayron D, Gennaro AR. Stability and compatibility of topotecan hydrochloride with selected drugs. Am J Health-Syst Pharm 1999 ; 56: 875-881.
1033	Lehti	Wolfe JL, Thoma LA, Du C, Goldspiel BR, Gallelli JF, Grimes GJ, Potti GK. Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide in 0.9% sodium chloride injection. Am J Health-Syst Pharm 1999 ; 56: 985-989.
1423	Lehti	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	Lehti	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1520	Laboratorio	Etude de stabilité des médicaments en Ecoflac® B Braun 2001
1613	Lehti	Lepage R, Walker SE, Godin J. Stability and compatibility of etoposide in normal saline. Can J Hosp Pharm 2000 ; 53: 338-345.
1722	Lehti	Gras C, Sautou-Miranda V, Bagel-Boithias S, Brigas F, Chopineau J. Compatibility of etoposide solution with polyvinyl chloride and low density polyethylene containers and its stability in different storage conditions. EJHP 2002 ; 2: 33-40.
1730	Lehti	Björkman S, Roth B. Chemical compatibility of mitoxantrone and etoposide (VP-16). Act Pharm Nord 1991 ; 3: 251.
1819	Lehti	Demoré B, Vigneron J, Perrin A, Hoffman MA, Hoffman M. Leaching of diethyl hexyl phtalate from polyvinyl chloride bags into intravenous etoposide solution. J Clin Pharm Ther 2002 ; 27: 139-142.
1895	Lehti	Bourdeaux D, Sautou-Miranda V, Bagel-Boithias S, Boyer A, Chopineau J. Analysis by liquid chromatography and infrared spectrometry of di(2-ethylhexyl)phtalate released by multilayer infusion tubing. J Pharm Biomed Anal 2004 ; 35: 57-64.
1984	Lehti	Bagel-Boithias S, Sautou-Miranda V, Bourdeaux D, Tramier V, Boyer A, Chopineau J. Leaching of diethylhexyl phtalate from multilayer tubing into etoposide infusion solutions. Am J Health-Syst Pharm 2005 ; 62: 182-188.
2108	Lehti	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2167	Lehti	Joel SP, Clark PI, Slevin ML. Stability of the iv and oral formulations of etoposide in solution. Cancer Chemother Pharmacol 1995 ; 37, 1: 117-124.
3574	Laboratorio	Ondansetron - Résumé des caractéristiques du produit Accord Healthcare France SAS 2013
3670	Lehti	Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. EJOP 2014 ; 8, 3: 26-30.
4024	Ilmoitus	Sadou Yaye H, Rieber Z, HassaniI L, Hoffmann-Martinot C, Babiard M, Aouti H, Bellanger A, Tilleul P. Pénurie mondiale d'Etopophos et conséquences pratiques : Intérêt des études de stabilité dans le choix d'un générique. SFPO Congress 2017 - Nantes 2017
4125	Lehti	D'Huart E, Vigneron J, Lider P, Demoré B. Physicochemical stability of etoposide diluted at range concentrations between 0.38 and 1.75 mg/mL in polyolefin bags. EJHP 2020 ; 27, 1: 43-48.
4304	Lehti	Klasen K, Kessari R, Mercier L, Valade C, Grill J, Desmaris R, Paci A. Stability of Etoposide Solutions in Disposable Infusion Devices for Day Hospital Cancer Practices. Drugs R D 2014 ; 14:13?23.
4352	Lehti	Li J, Yao C, Xu Y, Ping P, Yin H, Sun Y. In vitro compatibility and stability of admixtures containing etoposide, epirubicin hydrochloride and vindesine sulphate in a single infusion bag. J Clin Pharm Ther 2019 ; 44: 875-882.
4369	Lehti	Sadou Yayé H, Hassani L, Secrétan PH, Babiard M, Aouati H, Bellanger A, Tilleul P, Yagoubi N, Do B, Rietveld I. Physical and chemical stability of a generic etoposide formulation as an alternative to etoposide phosphate J Pharm Biomed Anal 2020 ;178:112896